Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02881710
NCT02881710CompletedNot Applicable

Variation IGFBP7 Markers and TIMP2 Induced by Injection of Contrast Iodized Drug at the Intensive Care Patient

Nantes University Hospital1 site in 1 country50 target enrollmentStarted: April 9, 2014Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
50
Locations
1
Primary Endpoint
significant increase in urinary concentrations of TIMP-2 and IGFBP7 defined as an increase of NephroCheck® test of more than 0.2 [ng / mL] 2/1000) after PCI injection
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Multicenter, prospective, uncontrolled study to evaluate variations in urinary concentrations of TIMP-2 and PCI IGFBP7 induced injection during a CT scan in intensive care patient.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Patients aged 18 years or more,
  • •Hospitalized in intensive care,
  • •Holders of a urinary catheter
  • •Patient receiving a first CT with intravenous injection of PCI during their ICU stay.
  • •Patient agreeing to participate in the research protocol

Exclusion Criteria

  • •Need to retain urine, whatever the reason (eg measurement of 24-hour proteinuria).
  • •Urine unanalyzable whatever reason (eg urinary washing with double current probe, injection is saline to measure bladder pressure.).
  • •Patient subjected to renal replacement
  • •Patient already included in the study for a previous injection of PCI in intensive care.

Outcomes

Primary Outcomes

significant increase in urinary concentrations of TIMP-2 and IGFBP7 defined as an increase of NephroCheck® test of more than 0.2 [ng / mL] 2/1000) after PCI injection

Time Frame: follow up: 5 days after injection

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Predicting renal failure using urine test in patients admitted in the ICU after trauma.
CTRI/2020/09/027662Department of Anaesthesiology and critical care JIPMER Puducherry79
Recruiting
Not Applicable
Role of chemicals in urine for predicting renal failure in patients with muscle injury
CTRI/2018/05/013824AIIMS intramural fund
Completed
Not Applicable
Application of the urinary biomarkers TIMP2 and IGFBP7 as early predictors regarding procedure selection for negative fluid balance in septic patientsN17R65.1Acute renal failureSystemic Inflammatory Response Syndrome of infectious origin with organ failure
DRKS00020212niversitätsklinikum Knappschaftkrankenhaus BochumKlinik für Anästhesiologie, Intensivmedizin und Schmerztherapie100
Completed
Not Applicable
Use of Urinary Cell-Cycle Arrest Biomarkers in Contrast-Associated Nephropathy After Coronary AngiographyContrast-induced Nephropathy
NCT04163250Eva de Miguel Balsa194
Completed
Not Applicable
TIMP-2 and IGFBP7 for the Prediction of the Cardiac Surgery Associated Acute Kidney InjuryAcute Kidney Injury
NCT02054546University Hospital, Basel, Switzerland110